CERVOMED INC. (CRVO)
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
General Announcement: Next Day Disclosure Return
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
Swiss Enterprises Build AI-Ready Cloud Infrastructure
Prologis, Inc. Announces Recommended Combination